P21

Description

P21 Research Peptide (CNTF-Mimetic) P21 is a premier synthetic reagent for neuroscience research, specifically engineered to investigate the restoration of neurogenic niches and synaptic plasticity. This synthetic peptide is a rationally designed “mimetic” molecule, meaning it distills the potent regenerative properties of human CNTF into a stable, blood-brain barrier-permeable form to achieve high-precision targeting of the central nervous system without the systemic toxicity of the parent protein. Key Research Features

Targeted Neurogenic Switch: Functions as a competitive inhibitor of Leukemia Inhibitory Factor (LIF) signaling. By blocking anti-proliferative signals, it shifts the neural environment from “scarring” (gliosis) to active neurogenesis. BDNF Amplification Cascade: Designed to study the robust upregulation of Brain-Derived Neurotrophic Factor (BDNF). This triggers the PI3K/Akt pathway, enhancing long-term potentiation (LTP) and ensuring the survival of newly formed neurons. Tau and Amyloid Modulation: A critical tool for researching the inhibition of GSK-3β, the kinase responsible for Tau hyperphosphorylation. It also promotes the non-amyloidogenic pathway by upregulating ADAM10 (α-secretase), potentially reducing Aβ plaque formation. Adamantylated Pharmacokinetics: Features a C-terminus adamantane moiety that confers high proteolytic resistance and superior blood-brain barrier permeability, ensuring therapeutic concentrations reach the brain even via peripheral administration.

Technical Specifications

Chemical Designation: Peptide 021 (P021) Sequence: Ac-DGGLAG-NH2 (Acetylated-Asp-Gly-Gly-Leu-Adamantylglycine-Amide)

Molecular Weight: ~578.3 g/mol
Purity: Research grade (High-purity synthetic entity)

Format: Lyophilized powder Pharmacology: Half-life exceeding 3 hours (significant improvement over native CNTF)

Applications in Research

Alzheimer’s & Neurodegeneration Modeling: Investigating the reversal of established cytoskeletal pathology, Tau reduction, and cognitive rescue in 3xTg-AD models. Traumatic Brain Injury (TBI) & CTE: Analyzing the proliferation of progenitor cells in the subgranular zone and the prevention of Tau-driven pathology following head impacts. Neuro-developmental Studies: Evaluating the rescue of neurogenesis deficits in models of Down Syndrome (Ts65Dn) to correct fundamental developmental trajectories. Ocular Research: Studying protective effects on the retina for conditions like Age-Related Macular Degeneration (AMD) by reducing lipofuscin and Aβ accumulation.

Research Use Only – Legal Disclaimer

All Eagle Peptides products labeled as Research Use Only (RUO) are intended strictly for laboratory, investigational, and scientific research purposes. These materials are not approved by the FDA and are not intended for human or veterinary use, clinical applications, diagnostic procedures, or therapeutic treatment of any kind. By purchasing or using RUO materials, you acknowledge that they will be handled only within an appropriate research environment by qualified personnel who understand the risks, limitations, and regulatory requirements associated with experimental compounds. Products must not be administered to humans or animals, offered as therapeutic agents, or represented as safe or effective for any medical purpose. Use of these materials is entirely at your own risk. Eagle Peptides assumes no liability for misuse, unsafe handling, improper application, or any regulatory or compliance issues arising from their use.